Similar results have been achieved by the applied activator of PKM2 activity (TEPP-46) in RRM1-overexpressing cells, indicating a better clinical efficacy in the treatment of gemcitabine and TEPP-46 on ESCC. The gene discussed is PKM; the disease is esophageal squamous cell carcinoma.